12:00 AM
 | 
Jan 01, 2007
 |  BioCentury  |  Finance

The good & the bad

The good & the bad

The good & the bad
Before the failure of Telcyta in two Phase III cancer trials last week, Telik (TELK) boasted one of the biggest market caps among biotechs...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >